Functional proteomics is emerging as the critical measurement layer between genomics and clinical decisions. HAWK Biosystems is looking for distribution partners who see what we see — and want to bring it to the world.
If you have imaging expertise, oncology and pathology relationships, and the conviction that science should drive better patient outcomes — we should talk.
Checkpoint inhibitors are the most important advance in cancer therapy in a generation. But the biomarkers used to select patients haven't evolved beyond measuring protein expression — a 40-year-old approach that fails to predict who will actually respond.
Immunohistochemistry (IHC) measures how much protein is present. It cannot tell you whether those proteins are actually doing anything.
Functional proteomics measures whether proteins are actually interacting at the molecular level — the ground truth of biological function.
Different technologies resolve molecular proximity at fundamentally different scales. Only FRET-FLIM operates in the range where protein-protein interaction actually occurs.
Optical co-occurrence of fluorescent signals. Cannot distinguish interaction from proximity.
EstablishedDNA-based proximity detection. Closer, but still cannot confirm molecular contact.
ImprovingEnergy transfer between fluorophores confirms direct molecular interaction. The physics guarantee it.
Only QF-Pro"Expression tells you who is in the building. QF-Pro tells you who is in the room, having the meeting that determines the patient's fate."
QF-Pro's clinical value is backed by peer-reviewed publications in top-tier journals — including the Journal of Clinical Oncology.
Source: Sanchez-Magraner et al. Journal of Clinical Oncology, 2023. n=188 NSCLC patients.
A complete ecosystem designed for clinical labs and research institutions, with built-in consumable revenue streams.
Benchtop FLIM microscope replacing room-sized systems. Modulated diode lasers, FLIM camera, 4-channel LED, 2×/20×/40× objectives.
Open kit design for any mouse/rabbit antibody pair. ATTO488 donor, Alexa594 acceptor, amplification reagents.
Integrated acquisition, analysis, and reporting. From ROI mapping to QF-Pro score output.
Functional proteomics is at an inflection point. The science is proven, the clinical need is urgent, and the competitive landscape is wide open.
No competing commercial platform operates at 1–10 nm interaction resolution in fixed tissue. Partners entering now define the category in their territories before competition emerges.
The JCO study establishes clinical validity. QF-Pro is on a path toward companion diagnostic (CDx) regulatory submissions — a transformation event for distribution partners already established in clinical oncology.
PD-1/PD-L1 is the first validated axis. TIGIT/CD155, CTLA-4/CD80, and LAG-3/MHC-II are in development — each new axis multiplies the clinical utility and reagent demand per instrument.
The platform measures any protein-protein interaction in fixed tissue. Neurodegenerative diseases, autoimmunity, cardiovascular — the same instruments and kits serve expanding applications.
We're seeking distribution partners who combine technical credibility with commercial reach. The ideal partner doesn't just sell instruments — they understand the science behind them and can articulate why measuring function changes everything.
Exclusive or semi-exclusive territories based on market coverage and commitment.
Comprehensive product training for sales and application scientists, with ongoing support from HAWK's team.
Publication reprints, webinar access, glossary resources, and co-branded marketing materials.
Instrument loans and sample processing support for customer evaluations and key opinion leader engagements.
Early access to new checkpoint assay validations, CDx regulatory progress, and publication data.
If you see the opportunity in measuring what proteins are doing rather than simply counting them — let's talk about building something significant together.